MENU
+Compare
MCRB
Stock ticker: NASDAQ
AS OF
Jan 14 closing price
Price
$16.08
Change
+$0.11 (+0.69%)
Capitalization
144.38M

MCRB Seres Therapeutics Inc Forecast, Technical & Fundamental Analysis

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States... Show more

Industry: #Biotechnology
MCRB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for MCRB with price predictions
Jan 14, 2026

MCRB in +1.52% Uptrend, advancing for three consecutive days on January 14, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MCRB advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 06, 2026. You may want to consider a long position or call options on MCRB as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on January 05, 2026. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MCRB broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MCRB entered a downward trend on January 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MCRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.305) is normal, around the industry mean (27.929). P/E Ratio (18.136) is within average values for comparable stocks, (51.397). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.899). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (0.792) is also within normal values, averaging (329.547).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
MCRB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of novel treatments for diseases related to the human microbiome

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
101 Cambridgepark Drive
Phone
+1 617 945-9626
Employees
233
Web
https://www.serestherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COLZF1.550.15
+10.71%
Coca Cola Icecek Sanayi As
HAYAF0.060.01
+9.16%
Hayasa Metals Inc.
YGTFF0.150.01
+7.66%
GOLD TERRA RESOURCE CORP.
DGTCF0.55N/A
-0.18%
DIGITAL CORE REIT MGMT PTE LTD.
HRNNF37.98-0.09
-0.24%
Hydro One Ltd

MCRB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with ORMP. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
+0.69%
ORMP - MCRB
42%
Loosely correlated
+7.37%
AXON - MCRB
38%
Loosely correlated
-1.92%
AMRN - MCRB
36%
Loosely correlated
-0.99%
ARRY - MCRB
34%
Loosely correlated
-6.70%
TAOX - MCRB
34%
Loosely correlated
+9.19%
More